{"id":"epirubicin-cyclophosphamide-paclitaxel-dabepoetin-alfa","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Thromboembolism (dabepoetin-associated)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epirubicin and cyclophosphamide are alkylating agents and topoisomerase inhibitors that cross-link DNA and prevent cancer cell replication. Paclitaxel stabilizes microtubules to disrupt cell division. Dabepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to increase hemoglobin levels in chemotherapy-induced anemia. This combination is designed to maximize cytotoxic effect while managing treatment-related side effects.","oneSentence":"This combination regimen uses chemotherapy agents (epirubicin, cyclophosphamide, paclitaxel) to damage cancer cell DNA and inhibit microtubule function, while dabepoetin alfa stimulates red blood cell production to counteract chemotherapy-induced anemia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:10.120Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (likely early-stage or metastatic, based on typical EC-T regimen use)"}]},"trialDetails":[{"nctId":"NCT00544232","phase":"PHASE3","title":"Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2002-08","conditions":"Breast Cancer","enrollment":720}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa","genericName":"Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa","companyName":"GBG Forschungs GmbH","companyId":"gbg-forschungs-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen uses chemotherapy agents (epirubicin, cyclophosphamide, paclitaxel) to damage cancer cell DNA and inhibit microtubule function, while dabepoetin alfa stimulates red blood cell production to counteract chemotherapy-induced anemia. Used for Breast cancer (likely early-stage or metastatic, based on typical EC-T regimen use).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}